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1. Summary
Mutations in five unconventional myosin genes have been associated with genetic
hearing loss (HL). These genes encode themotor proteinsmyosin IA, IIIA,VI, VIIA
and XVA. To date, most mutations inmyosin genes have been found in the Cauca-
sian population. In addition, only a few functional studies have been performed on
the previously reported myosin mutations. We performed screening and func-
tional studies for mutations in the MYO1A and MYO6 genes in Korean cases of
autosomal dominant non-syndromic HL. We identified four novel heterozygous
mutations in MYO6. Three mutations (p.R825X, p.R991X and Q918fsX941) pro-
duce a premature truncation of the myosin VI protein. Another mutation,
p.R205Q, was associated with diminished actin-activated ATPase activity and
actin gliding velocity of myosin VI in an in vitro analysis. This finding is consistent
with the results of protein modelling studies and corroborates the pathogenicity of
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this mutation in the MYO6 gene. One missense variant,
p.R544W, was found in theMYO1A gene, and in silico analysis
suggested that this variant has deleterious effects on protein
function. This finding is consistent with the results of protein
modelling studies and corroborates the pathogenic effect of
this mutation in the MYO6 gene.
2. Introduction
Myosins comprise a large family of motor proteins in eukary-
otic tissues. While originally described in muscle tissue,
another form of myosin, called unconventional myosin, has
been found in many other tissues [1,2]. Unconventional myo-
sins are associated with a diverse number of functions,
including endocytosis, the regulation of ion channels and
the movement of vesicles in the cytoplasm [3]. In the inner
ear, myosins are expressed in the stereocilia and the cell
body of the inner and outer hair cells. They bind actin fila-
ments and hydrolyse adenosine triphosphate (ATP) to
generate force and movement as well as to anchor hair cell
stereocilia of the inner ear [4]. This arrangement enables the
stereocilia to bend to sound waves, thereby opening ion chan-
nels, which allows for the transduction of sound (the
conversion of sound waves to nerve impulses) [5].
To date, mutations in five different types of unconventional
myosins—myosin IA (MYO1A), myosin IIIA (MYO3A),myosin
VI (MYO6), myosin VIIA (MYO7A) and myosin XVA
(MYO15A)—have been identified in hereditary hearing loss
(HL) [6–13]. Among these, the MYO1A (OMIM 601478) and
MYO6 (OMIM 600970) genes have been identified as the
cause of autosomal dominant non-syndromic hearing loss
(ADNSHL) [10,13]. MYO1A, which is also known as the
brush border myosin-I gene, is located at the DFNA48 locus
on chromosome 12, and thus far, eight different mutations
have been identified in Italy in patients with HL [13,14]. The
role of MYO1A in the inner ear and the impact of MYO1A
mutations on HL in general, however, remain unclear. MYO6
is located on chromosome 6 [10,12]. Mutations in the
MYO6 gene cause both ADNSHL (DFNA22) and autosomal
recessive non-syndromic hearing loss (DFNB37). Previous
studies have reported that myosin VI transports cargo mol-
ecules at the base of stereocilia, anchors actin filaments to the
membrane of stereocilia by cargo molecules in the inner ear
and is a mechanism for HL in myosin VI-null mice [15,16].
To date, most missense mutations among the previously
reported mutations in the myosin family have only been
described at the genome level. All known missense muta-
tions are important for the protein’s structure and function
because their residue positions are highly conserved among
many species. Therefore, a functional evaluation in vitro or
in vivo is required for an accurate characterization of the
mutated proteins.
In this study, we identifiedMYO1A andMYO6mutations
in patients with ADNSHL in Korea and analysed the molecu-
lar reasons for the pathogenic effect of novel mutations using
in silico and in vitro analyses.
3. Results
3.1. Mutation screening of MYO6 and MYO1A
We sequenced the MYO6 and MYO1A genes in 53 unrelated
Korean ADNSHL patients. Table 1 shows the four novel het-
erozygous mutations that were identified in the coding
regions of the MYO6 gene. Two nonsense mutations,
p.R825X and p.R991X, were identified in exons 24 and 28 of
MYO6, respectively. The p.R825X mutation was detected in
patient II-5 of the SR-149 family (figure 1a). This mutation is
a C to T transition at nucleotide position 2473 (c.2473 C. T),
which results in a stop codon in the IQ domain of the
neck region. The p.R991X mutation was identified in the
YS-052 family (figure 1b). The single-nucleotide change of C
to T at nucleotide position 2971 (c.2971 C. T) introduced
a stop codon corresponding to amino acid position 991.
This stop codon causes the protein to lose part of the globular
domain of the tail region. Patient II-2 of the SR-157 family had a
single-nucleotide insertion at position 2752 (c.2752insA) in
exon 26 (figure 1c). This mutation causes a frameshift that
first results in the introduction of 23 new amino acids after
the amino acid at position 917 (p.Q918fsX941) and then results
in a truncated form of myosin VI. A fourth mutation was
detected in patient III-1 of the SR-107 family (figure 1d). This
missense mutation was a G to A nucleotide change at position
614 (c.614 G. A), which changes an Arg residue to a Gln at
amino acid position 205 (p.R205Q) (figure 1d ). The arginine
at position 205 is conserved among myosins frommany differ-
ent species [17]. The previously solved X-ray structure of
Dictyostelium myosin II suggested that Arg238 (corresponding
to Arg205 of human myosin VI) in the switch I region [18]
forms a salt bridge with Glu459 in the switch II region [19].
Therefore, it is anticipated that the p.R205Q mutation in
human myosin VI disrupts this salt bridge, which will hamper
motor activity. To predict whether this non-synonymous
amino acid variant is likely to have a deleterious effect on the
phenotype, two prediction programs, PolyPhen2 and SIFT,
were applied. The results of both programs indicated that the
variation would have a deleterious effect, with a PolyPhen2
score of 1.000 and a SIFT score of 0.00.
Table 1. Mutations in the MYO6 gene (n.a., not available).
exon nucleotide change amino acid change time of onset phenotype shape of audiogram
8 c.614G. A p.R205Q ﬁrst decade progressive, mild to moderate U-shaped or ﬂat
24 c.2473C. T p.R825X n.a. progressive, moderate to
profound
down-sloping
26 c.2752insA p.Q918fsX941 ﬁfth decade progressive, moderate ﬂat
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In theMYO1A gene,we identified one variantwith aG toA
substitution at nucleotide position 1630 (c.1630 G. A) in
patient FTM-01. This variant converts a highly conserved
Arg to a Trp at amino acid position 544 (p.R544W; figure 1e).
The results of both prediction programs showed that the vari-
ation would have a deleterious effect, with a PolyPhen2 score
of 0.998 and a SIFT score of 0.00. None of the five aforemen-
tioned variants identified in this study were detected in any
of the hundred normal-hearing Korean participants who
were examined as controls.
Overall, we found one and four mutations inMYO1A and
MYO6 in this study, respectively. Figure 2 shows the
locations of these mutations.
3.2. Protein structure of mutant myosin VI and IA
We inspected the MYO6 homology model to determine the
structural differences between the wild-type and mutant
types, p.R205Q. Arg205 has hydrogen bonds and ionic inter-
actions with several surrounding residues, but the p.R205Q
mutation loses all of the ionic interactions because Gln is an
uncharged residue (figure 3a). Because of the smaller size of
Gln, most of the hydrogen bonds are also likely to be lost. In
addition, we inspected theMYO1A homology model to deter-
mine the possible molecular effects of the p.R544W variant.
The Arg544 residue in the motor domain of myosin 1A is
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Figure 1. Pedigree and genetic information for patients with novel mutations in the MYO6 and MYO1A genes. The lineages (a) SR-149, (b) YS-052, (c) SR-157 and
(d ) SR-107 exhibit autosomal dominant inheritance patterns. Two nonsense mutations, one frameshift mutation and one missense mutation were identified in these
families by direct sequencing (c: reverse sequence). The arginine at amino acid position 205 of myosin VI is highly conserved among several species. (e) DNA
sequence shows the p.R544W variant in the MYO1A gene. A comparison of amino acid sequences of myosin IA between several species. The asterisk indicates
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surrounding residues (figure 3b). The larger and hydrophobic
side chain that is introduced by p.R544W cannot form these
hydrogen bonds and thus destabilizes the motor domain.
3.3. Actin-activated ATPase activity and in vitro motility
activity of missense mutation in MYO6
We examined the effect of the p.R205Q mutation on the ATP
hydrolysis-associated motor activity of full-length human
myosin VI (M6Full). The p.R205Q myosin VI hydrolysed ATP
in the presence of Mg2þ at a constant rate similar to that of
the wild-type in the absence of actin. The results suggest that
the p.R205Q mutation abolishes neither ATP binding nor
hydrolysis. The actin-activated ATPase activity of the wild
type (M6Full WT) in 0.1 mM CaCl2 showed a KATPase value
that was similar to the tail-truncated mouse myosin VI
(M6S1) previously reported [20], and the Vmax was approxi-
mately half of the Vmax of M6S1. However, the KATPase of
M6Full WT in ethylene glycol tetraacetic acid (EGTA) was
more than 10-fold higher than that in 0.1 mM CaCl2 and that
of M6S1 in EGTA [20]. These results suggest that the tail por-
tion of the molecule interferes with the interaction with actin in
the presence of EGTA. The p.R205Q mutation, however, sig-
nificantly diminished the actin-activated ATP hydrolysis
cycle, which is coupled to the mechanical function of myosin
VI. The major effect of the mutation was the significant
decrease in Vmax rather than a change in KATPase (figure 4). In
addition, we tested in vitro motility activity of M6Full WT and
M6Full R205Q myosin VI full length to study interaction of
F-actin and myosin. As a result, the velocity of rhodamine-
phalloidin labelled F-actin movement was significantly
decreased by p.R205Qmutation (figure 5). These results indicate
that p.R205Q mutation causes a decrease in the actin-activated
ATPase activity, and hampers F-actin movement.
4. Discussion
Several studies have reported that mutations in unconventional
myosin proteins cause HL in the Caucasian population [6–13].



















Figure 3. Protein structures of missense mutations in myosin VI and myosin Ia. These images show protein modelling of (a) WT and p.R205Q of myosin VI as well
as (b) WT and p.R544W in myosin IA. These images show a close-up of the mutation site. (a) Green, arginine; red, glutamine; magenta, ATP; orange, glutamic acid
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in Snell’s waltzer mouse. This strain carries a spontaneous
recessive mutation that results in protein deficiency by frame-
shift mutation (130 bp deletion) [15]. Since then, seven
different mutations in the MYO6 gene have been reported to
be associated with DFNA22 deafness in Caucasian families:
three missense mutations (p.H246R, p.C442Y and p.R1204W),
a nonsense mutation (p.R849X), two splicing mutations
(c.897G. T and c.2416 þ 2321T. G) and an overexpression
mutation [10,21–25]. In addition, three unrelated Pakistani
families exhibited homozygosity for three different mutations
associated with DFNB37 deafness (c.36insT, p.E216V and
p.R1166X) [12]. A number of studies have revealed MYO6
mutations in the Caucasian and Pakistani populations; how-
ever, mutations have not previously been reported in East
Asian populations. Our study of Korean patients with
ADNSHL identified four novel mutations in the MYO6 gene
that appear to be causally related to deafness. These mutations
were neither observed in normal-hearingKorean controls nor in
the 1000 Genomes Database and are thus far unique to the
Korean deaf population.
MyosinVI is expressed in the early stage of hair cell differen-
tiation [26]. It is located in the hair cell body, the cuticular plate,
the pericuticular necklace of hair cells, and between actin and
the membrane of stereocilia of hair cells of the organ of Corti
[5,27]. The myosin VI dimer can move with a cargo molecule
towards the minus end of an actin filament [28]. Moreover, it
has been suggested that myosin VI plays an important role in
the generation and maintenance of hair cell stereocilia [29],
which has been shown in several in vivo studies using myosin
VI null mice with stereocilia fusion and growth of giant hair
cell stereocilia in the cochlea [15,16].
Myosin VI has three functional domains: an N-terminal
motor domain or head domain, a C-terminal tail domain and
a so-called neck region. The N-terminal motor domain has
ATPase activity and binds to actin molecules, whereas the tail
domain contributes to the dimerization of myosin molecules
and cargo binding. The neck region is located between the
head and tail domains, and contains light chain- or calmodu-
lin-binding IQ motifs [3,30,31]. Myosin VI is a motor protein
that uses energy derived from ATP hydrolysis by actin-
activated ATPase [31], and half of all myosin VI mutations
have been found in the motor domain [10,12,21,23]. Because
Snell’s waltzer mouse with an alternatively spliced, trunca-
ted myosin VI protein has shown disturbing dimerization
[15,23], we expect that the two nonsense mutations and the fra-
meshift mutation disrupt dimerization in a similar manner,
resulting in a myosin VI null phenotype. In addition, the
p.R238E mutation of Dictyostelium myosin II [32–34] and
the p.R247A/p.R247E mutation of smooth muscle myosin II
[35] were previously reported to abolish actin-activated
ATPase activity. The present functional studies revealed that
mutation of the conserved Arg205 to Gln does not abolish the
actin activity of myosin VI but significantly decreases Vmax.
Because the Gln side chain contains the –NH2 group, it is poss-
ible that it can still form a hydrogen bond with the Glu side
chain in switch II, but we cannot exclude the possibility that
the active site pockets are slightly different between myosin II
and myosin VI. Taken together, these findings indicate that
the p.R205Q mutation causes a myosin VI null function via
reduced ATPase activity in the motor domain.
Myosin IA is one of the most abundant components of the
enterocyte brush border, and plays critical roles in the interface
between the membrane and actin cytoskeleton [36]. The
p.E385D missense mutation is considered causative largely
because it was demonstrated to disrupt actin movement by
lowering ATPase activity [37]. We observed one variant,
p.R544W, in the MYO1A gene. This Arg544 residue is located
in a conserved region of the myosin IA motor domain in ver-
tebrates. Our in silico analyses suggest that p.R544W may be
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Figure 4. ATPase activity of missense variant (p.R205Q) of myosin VI. This image is F-actin-activated ATPase activity of WT and p.R205Q. Triangles, reaction buffer















Figure 5. Multi-molecule in vitro motility activity of wild-type and p.R205Q
mutant of myosin VI. This image shows in vitro motility activity of WT (open





 on February 27, 2015http://rsob.royalsocietypublishing.org/Downloaded from 
destabilization of the motor domain because hydrogen bonds
cannot be formed. However, further in vivo or in vitro analy-
ses are required to determine whether this variant is truly
causative or whether it is a rare polymorphism.
In conclusion, we identified five novel mutations inMYO1A
andMYO6, and analysed their characteristics by in vitro and in
silico analyses.We explained in detail that the p.R205Qmutation
in myosin VI decreases ATPase activity significantly.
5. Material and methods
5.1. Subjects and clinical evaluations
We selected 53 unrelated Korean patients with non-syndromic
HL whose families exhibited an autosomal dominant inheri-
tance pattern. All subjects were recruited from the Yonsei
University Hospital, Seoul, Korea, the Soree Ear Clinic, Seoul,
Korea or the PatimaHospital, Daegu, Korea. Following a phys-
ical and otoscopic examination, pure tone audiometry (PTA)
was performed in a sound-attenuated room. We determined
the average thresholds for a frequency range of 250–8000 Hz.
One hundred unrelated Koreans diagnosed as normal by PTA
test were recruited as control subjects.
5.2. Genetic analysis
Genomic DNA was extracted from peripheral blood using a
FlexiGene DNA extraction kit (Qiagen, Hilden, Germany) or
from buccal cells using a Puregene Buccal Cell Core kit
(Qiagen). To analyse the MYO1A and MYO6 gene sequences,
all of the exons and exon–intron boundary regions in each
gene were amplified by polymerase chain reaction (PCR)
using specifically designed primer pairs. We performed
cycling PCR using an ABI Big Dye Terminator v. 3.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, CA). PCR
products were sequenced using an ABI 3130XL genetic analy-
ser (Applied Biosystems). The sequence data were analysed
using CHROMAS PRO (v. 1.5) software (Technelysium, Pty Ltd.,
Tewantin, Queensland, Australia) and SEQSCAPE (v. 2.5) soft-
ware (Applied Biosystems), and the sequences were
compared with the corresponding sequences in GenBank
(accession no. NM_001256041.1 for MYO1A and accession
no.NM_004999.3 forMYO6). The amino acid sequences of var-
ious vertebrate species were aligned using the CLUSTAL W2
program (http://www.ebi.ac.uk/Tools/msa/clustalw2/) to
evaluate whether amino acid substitutions occur in conserved
regions of the proteins. The pathogenic effect of these substi-
tutions was predicted using SIFT (http://sift.jcvi.org/) and
PolyPhen2 (http://genetics.bwh.harvard.edu/pph2).
5.3. Protein modelling
Because no experimentally solved structures exist for either
MYO1A or MOY6, we built homology models for these pro-
teins. The YASARA and WHAT IF Twinset was used (with
default parameters) for model building and subsequent ana-
lyses [38]. The model for MYO1A was constructed using the
PDB file 2dfs [39] as a template. This file contains the structure
for myosin V from chicken, which is 37% identical toMYO1A
over 770 residues. The modelled domain of MYO1A contains
the location of the newly identified mutation p.R544W. The
model for myosin VI was constructed from myosin VI of
wild boar, which is 98% identical to the human sequence
over 784 residues [40]. The point mutations inMYO6were ana-
lysed using this model.
5.4. Generation of myosin VI constructs and isolation
of the proteins
Human myosin VI cDNA clones containing nucleotides
1–1285 were obtained from a human kidney cDNA library
and inserted into the pFastbac1 (Invitrogen, Carlsbad, CA)
baculovirus transfer vector at the polylinker region. For
wild-type recombinant myosin VI (M6FullWT), a c-myc
and FLAG tag sequence (ACGCGTGAGCAAAAGCTCA
TTTCTGAAGAGGACTTGTCGCGTGATTATAAAGATGAT
GATGATAAA) was introduced between the 30 end of the
myosin VI cDNA and the stop codon to aid purification of
the recombinant protein. The p.R205Q mutation of myosin
VI was generated by PCR-based site-directed mutagenesis
[41] using Pfu DNA polymerase. The presence of the mutation
was confirmed by sequencing. Expression and purification
of the recombinant myosin VI was performed as described
previously [20].
5.5. ATPase assay
ATPase activity was measured at 258C in a buffer that
contained 30 mM KCl, 20 mM MOPS-KOH (pH 7.5), 3 mM
MgCl2, 2 mM ATP, 5 mM CaM, 40 unit ml
21 pyruvate kinase,
2.5 mM phosphoenolpyruvate, 1 mM EGTA or 0.2 mM
CaCl2, 11–14 mg ml
21 M6Full WT or the mutant, and various
concentrations of F-actin ranging from 0 to 104 mM. The liber-
ated pyruvatewas determined as described previously [42]. To
calculate the ATPase activity, protein concentrations of M6Full
WT and the mutant were determined using Coomassie Plus
Assay Reagent (Thermo Scientific, Waltham, MA). The mol-
ecular weight of M6Full WT was assumed to be 185 kDa
(151.4 kDa M6 heavy chain and 2  16.8 kDa calmodulin
light chains).
5.6. In vitro motility assay
In vitro motility of Rhodamine-labelled F-actin was measured
using a cooled-CCD camera (Sensi CamQE, Cooke Co.)
equipped with an Olympus IX-51-based fluorescence micro-
scope [20]. The assay was carried out in a buffer containing
25 mM KCl, 20 mM MOPS-KOH (pH7.5), 5 mM MgCl2,
1 mM EGTA, 2 mM ATP, 216 mg ml21 glucose oxidase,
36 mg ml21 catalase, 4.5 mg ml21 glucose, 10 mM dithiothrei-
tol, 5 mM calmodulin and 15 nM F-actin at 218C. Each of
wild-type and the mutant M6Full with the appropriate con-
centration was attached to the same coverslip separated
with double-adhesive tape, and F-actin movements were cap-
tured at every 2 (wild-type) or 8 (p.R205Q) seconds. The
velocity was calculated from the distance and the elapsed
time in the video images.
This study was approved by the Institutional Review Board of the
Yonsei University College of Medicine, and written informed consent
was obtained from all participants.
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